GENE ONLINE|News &
Opinion
Blog

2022-03-08| Special

From Forbidden Drugs to Psychotropic Cures: A “Psychedelic Boom” Breaks New Ground in Treating Mental Illnesses

by GeneOnline
Share To
More than 30% of adults worldwide have experienced generalized anxiety disorder and 5% suffer from depression, not including the population with other mental illnesses such as attention deficit hyperactivity disorder (ADHD) or post-traumatic stress disorder (PTSD).

Based on statistics, the estimated revenue of the U.S. mental health market was $397.4 billion and the global market size is expected to grow to more than $500 billion by 2030.
The market growth has brought about the rise of novel treatments. Psychedelics, a family of highly controversial drugs, are being gradually destigmatized and attracting attention from scientists and investors. What are the most common psychedelics? 

GO Prime with only $1.49 now

LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!